Coherus BioSciences Inc. (CHRS)

15.50
NASDAQ : Health Technology
Prev Close 15.95
Day Low/High 15.40 / 16.05
52 Wk Low/High 8.05 / 24.70
Avg Volume 726.90K
Exchange NASDAQ
Shares Outstanding 61.16M
Market Cap 996.96M
EPS -4.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

AbbVie Notches Legal Win Over Coherus

But AbbVie still contends it should retain exclusivity on its lucrative Humira into the next decade.

AbbVie Stock Higher on Humira Patent Win

AbbVie Stock Higher on Humira Patent Win

The Patent Trial and Appeal Board has denied Coherus's petition to make a copy of AbbVie's Humira drug.

Momenta, Coherus BioSciences Are Both Good Options in the Biosimilar Space

Momenta, Coherus BioSciences Are Both Good Options in the Biosimilar Space

Momenta may be a good option for value-oriented investors, while Coherus may be better for those who prefer a company that is likely to gain momentum.

Coherus BioSciences Regains Development And Commercial Rights To CHS-0214 From Shire

Coherus BioSciences Regains Development And Commercial Rights To CHS-0214 From Shire

No Payment Due upon Return, no Obligations for Future Payments or Royalties

AbbVie's Battle Royale

AbbVie's Battle Royale

Year to date, shares of AbbVie are up 7%. With a gigantic patent battle looming, can the stock go higher?

Coherus BioSciences Reports Second Quarter 2016 Financial And Operating Results

Coherus BioSciences Reports Second Quarter 2016 Financial And Operating Results

Continued execution on multiple fronts positions the company strongly for the second-half of 2016 and beyond

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

Coherus BioSciences Provides Update On IPRs

Coherus BioSciences Provides Update On IPRs

Patent Trial and Appeal Board Institutes Two Additional IPRs Against AbbVie's Patents

Coherus Presents Study Results Demonstrating Equivalence Of Its CHS-0214 Biosimilar To Etanercept

Coherus Presents Study Results Demonstrating Equivalence Of Its CHS-0214 Biosimilar To Etanercept

Biosimilar to etanercept meets primary endpoint

Coherus BioSciences Advances Differentiated IP Strategy For Humira Market Access

Coherus BioSciences Advances Differentiated IP Strategy For Humira Market Access

USPTO Issued Coherus U.S. Patents 9,340,611; 9,340,612 and 9,346,880

2 Big -- and Mispriced -- Biotech Stocks

AbbVie and Gilead Sciences are worth accumulating in a long and deep bear market for biotech.

Coherus BioSciences Provides Update On '135 IPR

Coherus BioSciences Provides Update On '135 IPR

Patent Trial and Appeal Board Institutes

TheStreet Quant Rating: D- (Sell)